| Day / Time |
Topic |
Speaker(s) |
| 07.30-08.30 |
Meet the Professors Breakfast 1
(limited to 45 pax)
Skin toxicity of tyrosine kinase inhibitors and the
relationship to efficacy |
Chair: Gary Richardson
Speaker: Roman Perez-Soler |
| 07.30-08.30 |
Meet the Professors Breakfast 2
(limited to 40 pax)
The ibs and abs of colorectal cancer |
Chair: Catherine Shannon
Speaker: Eva Segelov
|
| 08.45-09.00 |
Welcome to Country and Opening Ceremony
Her Excellency Professor Marie Bashir AC CVO, Governor of New South Wales |
Chair: Stephen Della-Fiorentina |
| 09.00-10.45 |
Symposium 1- Targeted Therapies |
Chair: Catherine Shannon |
| 09.00-09.20 |
Why we need to select the right patients for the right drugs and the right drugs for the right patients |
Paul Waring |
| 09.20-09.40 |
Urothelial carcinoma - can we individualise our approach? |
David Quinn |
| 09.40-10.00 |
Targeted therapy in Non-small
cell lung cancer |
Roman Perez-Soler |
| 10.00-10.20 |
Integrating targeted therapies in lung cancer: target practice or have we found the five hole? |
Peter Ellis |
| 10.20-10.45 |
Discussion |
Panel |
| 10.45-11.15 |
Morning Tea |
|
11.15-12.45 |
Symposium 2- Survivorship |
Chair: Diana Adams |
| 11.15-11.30 |
Cancer Survivorship - an overview |
Michael Jefford |
|
11.30-11.50 |
Measurement of unmet need |
Phyllis Butow |
| 11.50-12.10 |
The potential role of primary care in cancer survivorship |
Jon Emery |
| 12.10-12.30 |
Post treatment care - nursing perspective |
Sanchia Aranda |
| 12.30-12.45 |
Discussion |
Panel |
| 12.45-13.45 |
Lunch / MOGA AGM |
| 13.45-15.00 |
Trainees' Proffered Paper Session |
Chair: Michael Michael |
| 13.45-14.00 |
Adjuvant Lipiodol I-131 in Resected Hepatocellular Carcinoma: A Retrospective Review of 22 Patients. |
Deme Karikios |
| 14.00-14.15 |
Mortality Within 30 and 60 Days of Receiving Systemic Anti-cancer Therapy at a Regional Oncology Unit |
Jaclyn Yoong |
| 14.15-14.30 |
Cardiac Dysfunction in Patients Receiving Trastuzumab for Early Stage Breast Cancer in the SESIAHS |
Charlotte Lemech |
| 14.30-14.45 |
Anal Cancer Treatment: Can Quality Advancements be Made? |
Lina Pugliano |
| 14.45-15.00 |
Bleomycin Dosing for Germ Cell Tumours - Are We Too Cautious? |
Baerin Houghton |
| 15.00-15.30 |
Afternoon Tea |
| 15.30-16.30 |
Viewpoint Session "The tension between evidence - based medicine and personalised medicine" |
Chair: Paul de Souza
Discussants: Grant McArthur and John Simes |
| 16.30-17.30 |
Best of the Best Poster Session |
Chair: Peter Ellis |
| 16.30-16.40 |
Patients treated with platinum doublet chemotherapy for advanced non-small cell lung cancer have
inferior outcomes if previously treated with platinum-based chemo-radiation
|
Ashvin Paramanathan |
| 16.40-16.50 |
Cart-wheel.org: advancing the
study of rare tumours |
Maggie Moore |
| 16.50-17.00 |
Late fatigue after adjuvant therapy for breast cancer is largely unrelated to cancer or its treatment: 5
year follow up of a prospective cohort study
|
Kate Webber |
| 17.00-17.10 |
Management of small cell lung cancer (SCLC) in Victoria in 2003 |
Gary Richardson |
| 17.10-17.20 |
Glutathione S-transferase Pi (GSTPi) for prediction of chemotherapy response and survival in stage IV colorectal cancer |
Wei Chua |
| 17.20-17.30 |
Skeletal-related events (SRES) in patients with advanced solid tumours or multiple myeloma with
bone metastases (BM): results from a phase 3 randomized, double-blind, double-dummy trial
comparing denosumab with zoledronic acid (ZA)
|
Anthony Glennane |
| 17.30-18.30 |
Poster Walk-around Session (with drinks) |
| 19.00-22.00 |
BMS Platinum Sponsor Dinner Symposium 
"The Immune System and Cancer: a focus on monoclonal antibodies"
Speakers: Jim McCluskey, University of Melbourne and
Ian Davis, Ludwig Cancer Institute, Austin Hospital |
Multiple pathways, singular vision: Working with you to improve patient's lives
